Efficacy
Movement Disorder, Parkinson’s Disease Rating Scale, SE
MOVEMENT DISORDER, SECONDARY
The primary endpoint of change from predose to 90 min postdose in MDS-UPDRS Part III score at week 4 was comparable for SL-APO and SC-APO (least squares [LS] mean [standard error], –13.6 [1.5] vs. –13.8 [1.5]; Change from predose in MDS-UPDRS Part III score at week 4 over time (treatment phase mITT population). Data represent MDS-UPDRS Part III scores achieved with the optimized dose of each apomorphine formulation at week 4 of the treatment phase. LS, least squares; MDS-UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating Scale; mITT, modified intention-to-treat; SC-APO, subcutaneous apomorphine; SE, standard error; SL-APO, apomorphine sublingual film.The secondary endpoints of investigator- and patient-rated durability of response were comparable between SL-APO and SC-APO at week 4 (investigator-rated predicted response rate, 11.8% vs. 10.6% [Investigator- and patient-rated durability of responseThe secondary endpoint of patient preference for SL-APO over SC-APO was evaluated using the TPQ at study end, after patients completed both treatment periods. When patients were presented with the following statement: “Overall, the treatment I prefer for my OFF episodes is,” 72.2% preferred SL-APO compared with SC-APO/no preference (95% CI, 61.9–82.6; 